BioSpace News Archive

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2019.

CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, March 12, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2019 and to provide a business update.

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019, after the market closes on Thursday, March 12th, 2019, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

The U.S. Food and Drug Administration has embarked on a comprehensive evaluation of cannabidiol products, with a focus on educating the public about the risks and unknowns of these products, gathering the science needed to better understand both these safety concerns and potential benefits to inform our regulatory approach, as well as taking steps when necessary to address products that violate the law in ways that raise a variety of public health concerns.

Myomo, Inc. announced that it will report financial results for the fourth quarter and year ended December 31, 2019 on Thursday, March 12, 2020 after the market close.

The epidemic of COVID-19 remains a prominent healthcare challenge, affecting more than 70 countries and regions over the world.

Biocomposites, an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the launch of STIMULAN® Rapid Cure 3cc.

Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019..

Royalty Pharma announced that it has acquired Massachusetts General Hospital’s royalty interest in Entyvio for $94 million.

Coherus BioSciences, Inc., announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET, being held in Miami.